Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study

被引：0

作者：

le Coutre, Philipp D. ^{[1
]}

Giles, Francis J. ^{[2
,3
]}

Pinilla-Ibarz, Javier ^{[4
]}

Larson, Richard A. ^{[5
]}

Gattermann, Norbert ^{[6
]}

Ottmann, Oliver G. ^{[7
]}

Hochhaus, Andreas ^{[8
]}

Radich, Jerald P. ^{[9
]}

Saglio, Giuseppe ^{[10
]}

Hughes, Timothy P. ^{[11
]}

Martinelli, Giovanni ^{[12
]}

Kim, Dong-Wook ^{[13
]}

Branford, Susan ^{[11
]}

Mueller, Martin C. ^{[14
]}

Shou, Yaping ^{[15
]}

Novick, Steven ^{[16
]}

Fan, Xiaolin ^{[16
]}

Cortes, Jorge E. ^{[17
]}

Baccarani, Michele ^{[12
]}

Kantarjian, Hagop M. ^{[17
]}

机构：

[1] Charite, D-13353 Berlin, Germany

[2] Natl Univ Ireland Galway, Galway, Ireland

[3] Trinity Coll Dublin, Galway, Ireland

[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Univ Dusseldorf, D-40225 Dusseldorf, Germany

[7] Univ Klin Frankfurt, Med Klin 2, MRD Lab, Frankfurt, Germany

[8] Univ Klinikum Jena, Jena, Germany

[9] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[10] Univ Turin, Orbassano, Italy

[11] Royal Adelaide Hosp, SA Pathol, Adelaide, SA 5000, Australia

[12] Univ Bologna, Bologna, Italy

[13] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[14] Univ Heidelberg, Med Klin 3, Med Fak Mannheim, D-6800 Mannheim, Germany

[15] Novartis Inst BioMed Res, Cambridge, MA USA

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1610 / 1610

页数：1

共 50 条

[41] Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up
Saglio, Giuseppe
LeCoutre, Philipp D.
Pasquini, Ricardo
Jootar, Saengsuree
Nakamae, Hirohisa
Flinn, Ian W.
Hochhaus, Andreas
Hughes, Timothy P.
Larson, Richard A.
Hoenekopp, Albert
Gallagher, Neil J.
Yu, Richard
Blakesley, Rick E.
Kim, Dong-Wook
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 208 - 209
[42] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Quintas-Cardama, Alfonso
Kantarjian, Hagop
Michor, Franziska
Olshen, Adam
Gonen, Mithat
Jones, Dan
Rios, Mary Beth
O'Brien, Susan
Cortes, Jorge
BLOOD, 2008, 112 (11) : 1114 - 1115
[43] Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up
Shah, Neil
Kantarjian, Hagop
Hochhaus, Andreas
Cortes, Jorge E.
Bradley-Garelik, M. Brigid
Zhu, Chao
Baccarani, Michele
BLOOD, 2010, 116 (21) : 94 - 94
[44] Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib
Ritchie, Ellen K.
Catchatourian, Rosalind
Klisovic, Rebecca B.
Pinilla-Ibarz, Javier
Deininger, Michael W.
Erba, Harry P.
Radich, Jerald P.
Savona, Michael R.
Dautaj, Ilva
Purkayastha, Das
Habucky, Karen
Mauro, Michael J.
BLOOD, 2017, 130
[45] Pharmacokinetic analysis of nilotinib in Chinese chronic myelogenous leukemia (CML) patients (pts) with imatinib-resistant or-intolerant disease in blast crisis (BC), accelerated phase (AP) or chronic phase (CP)
Zhou, L.
Hu, P.
Meng, F.
Wang, J.
Wang, C.
Hu, Z.
Shen, Z.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[46] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
Hochhaus, A.
Giles, F.
Apperely, J.
Ossenkoppele, G.
Wang, J.
Gallagher, N. J.
Baccarani, M.
Cortes, J.
Kantarjian, H.
Le Coutre, P. D.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 256 - 256
[47] Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study
le Coutre, Philipp D.
Turkina, Anna
Kim, Dong-Wook
Ceglarek, Bernadeta
Alimena, Giuliana
Al-Ali, Haifa Kathrin
Shen, Zhixiang
Jootar, Saengsuree
Smith, Graeme
De Souza, Carmino Antonio
Dorlhiac-Llacer, Pedro Enrique
Rizzieri, David A.
Szczudlo, Tomasz
Berton, Myriam
Wang, Jim
Wang, Si-Tien
Nicolini, Franck Emmanuel
BLOOD, 2009, 114 (22) : 1272 - 1273
[48] Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study
Giles, Francis
le Coutre, Philipp D.
Bhalla, Kapil N.
Ossenkoppele, Gert J.
Alimena, Giuliana
Haque, Ariful
Gallagher, Neil J.
Kantarjian, Hagop M.
BLOOD, 2008, 112 (11) : 1110 - 1110
[49] Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up
Spector, Nelson
Leber, Brian
Lipton, Jeffrey Howard
De Souza, Carmino
Moiraghi, Beatriz
Steegmann, Juan Luis
Schwarer, Anthony P.
Cervantes, Francisco
Hughes, Timothy P.
Purkayastha, Das
Collins, LaTonya R.
Szczudlo, Tomasz K.
Rea, Delphine
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[50] DASATINIB TREATMENT OF IMATINIB-RESISTANT AND IMATINIB-INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN A CHRONIC PHASE
Vinogradova, O. Yu.
Turkina, A. G.
Vorontsova, A. V.
Chelysheva, E. Yu.
Gusarova, G. A.
Kuznetsov, S. V.
Goryacheva, S. R.
Sokolova, M. A.
Abakumov, E. M.
Stakhina, O. V.
Domracheva, E. V.
Misyurin, A. V.
Khoroshko, N. D.
TERAPEVTICHESKII ARKHIV, 2009, 81 (07) : 41 - 46

← 1 2 3 4 5 →